Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Onderzoek naar werkzaamheid en veiligheid van nipocalimab bij volwassenen met chronische inflammatoire demyeliniserende polyneuropathie (CIDP)

2 november 2026 bijgewerkt door: Janssen Research & Development, LLC

Fase 2/3, multistage, multicenter, gerandomiseerde, dubbelblinde, placebogecontroleerde terugtrekkingsstudie met parallelle groepen om de werkzaamheid en veiligheid te evalueren van nipocalimab toegediend aan volwassenen met chronische inflammatoire demyeliniserende polyneuropathie (CIDP)

The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

201

Fase

  • Fase 2
  • Fase 3

Uitgebreide toegang

Tijdelijk niet beschikbaar buiten de klinische proef. Zie uitgebreid toegangsrecord.

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Buenos Aires, Argentinië, C1199ABB
        • Actief, niet wervend
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, Argentinië, C1428AQK
        • Werving
        • Instituto Fleni
      • Buenos Aires, Argentinië, C1428
        • Voltooid
        • Hospital Gral Agudos Ignacio Pirovano
      • Rosario, Argentinië, 2900
        • Werving
        • INECO Neurociencias Orono
      • Melbourne, Australië, 3004
        • Voltooid
        • The Alfred Hospital
      • Parkwood, Australië, 4215
        • Voltooid
        • Gold Coast University Hospital
      • Ottawa, Canada, K1N 6N5
        • Werving
        • The Ottawa Hospital Ottawa NeuroMuscular Centre
      • Beijing, China, 100191
        • Voltooid
        • Peking University Third Hospital
      • Beijing, China, 100034
        • Voltooid
        • Peking University First Hospital
      • Beijing, China, 100053
        • Actief, niet wervend
        • Xuanwu Hospital ,Capital Medical University
      • Beijing, China, 100070
        • Actief, niet wervend
        • Beijing Tiantan Hospital, Capital Medical University
      • Changchun, China, 130021
        • Actief, niet wervend
        • The First Hospital of Jilin University
      • Changsha, China, 410008
        • Voltooid
        • Xiangya Hospital Central South University
      • Changsha, China, 410008
        • Actief, niet wervend
        • The Third Xiangya Hospital of Central Sourth University
      • Chengdu, China, 610072
        • Voltooid
        • Sichuan Provincial Peoples Hospital
      • Chifeng, China, 024000
        • Voltooid
        • Chifeng Municipal Hospital
      • Fuzhou, China, 350001
        • Actief, niet wervend
        • Fujian Medical University Union Hospital
      • Guangzhou, China, 510080
        • Actief, niet wervend
        • The First Affiliated Hospital Sun Yat sen University
      • Jinan, China, 250012
        • Actief, niet wervend
        • Qilu Hospital of Shandong University
      • Jinan, China, 250014
        • Voltooid
        • Qianfoshan hospital of Shandong Province
      • Nanchang, China, 330006
        • Actief, niet wervend
        • The First Affiliated Hospital of NanChang University
      • Shanghai, China, 200336
        • Voltooid
        • Tong Ren Hospital Shanghai Jiao Tong University school of medicine
      • Shanghai, China, 200040
        • Actief, niet wervend
        • Huashan Hospital Fudan University
      • Wuhan, China, 430023
        • Voltooid
        • Renmin Hospital of Wuhan University
      • Xi'an, China, 710032
        • Voltooid
        • Tangdu hospital the Fourth Military Medical
      • Xi'an, China, 710075
        • Actief, niet wervend
        • Xi 'an GaoXin Hospital
      • Floridablanca, Colombia, 681004
        • Voltooid
        • Fundación Cardiovascular de Colombia - Instituto del Corazón Floridablanca
      • Medellín, Colombia, 50021
        • Actief, niet wervend
        • Instituto Neurológico de Colombia
      • Berlin, Duitsland, 13347
        • Actief, niet wervend
        • Judisches Krankenhaus Berlin
      • Bochum, Duitsland, 44791
        • Voltooid
        • St. Josef-Hospital, Ruhr-Universität Bochum
      • Halle, Duitsland, 6120
        • Actief, niet wervend
        • Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH
      • Hanover, Duitsland, 30625
        • Actief, niet wervend
        • Medizinische Hochschule Hannover
      • Leipzig, Duitsland, 4103
        • Voltooid
        • Universitaetsklinikum Leipzig
      • Potsdam, Duitsland, 14471
        • Voltooid
        • St Josefs Krankenhaus Potsdam Sanssouci
      • Bordeaux, Frankrijk, 33000
        • Voltooid
        • CHU Bordeaux
      • Bron, Frankrijk, 69699
        • Voltooid
        • Hospices Civils de Lyon HCL
      • Le Kremlin-Bicêtre, Frankrijk, 94270
        • Actief, niet wervend
        • Hopital de Bicetre
      • Marseille, Frankrijk, 13385
        • Actief, niet wervend
        • Hopital de la Timone
      • Nice, Frankrijk, 06000
        • Actief, niet wervend
        • Hopital PASTEUR
      • Nîmes, Frankrijk, 30029
        • Actief, niet wervend
        • CHU Nimes Hopital Caremeau
      • Paris, Frankrijk, 75013
        • Voltooid
        • Hopital de la Pitie Salpetriere
      • Paris, Frankrijk, 75019
        • Voltooid
        • Fondation Adolphe de Rothschild Hospital
      • Strasbourg, Frankrijk, 67200
        • Actief, niet wervend
        • CHRU Strasbourg
      • Athens, Griekenland, 12462
        • Werving
        • Attikon General Hospital of Athens
      • Athens, Griekenland, 11527
        • Voltooid
        • Papageorgiou General Hospital Of Thessaloniki
      • Pátrai, Griekenland, 26504
        • Voltooid
        • Patras University Hospital
      • Thessaloniki, Griekenland, 54636
        • Werving
        • Ahepa Hospital Aristotle University of Thessaloniki
      • Catania, Italië, 95123
        • Voltooid
        • Azienda Ospedaliero-Universitaria Policlinico di Catania
      • Genova, Italië, 16132
        • Voltooid
        • Azienda Ospedaliera Universitaria San Martino di Genova
      • Milan, Italië, 20144
        • Voltooid
        • Casa di Cura del Policlinico
      • Milan, Italië, 20133
        • Voltooid
        • Istituto Neurologico Carlo Besta
      • Naples, Italië, 80131
        • Actief, niet wervend
        • Azienda Ospedaliera di Rilievo Nazionale A Cardarelli
      • Orbassano, Italië, 10043
        • Voltooid
        • Aou San Luigi Gonzaga
      • Pavia, Italië, 27100
        • Voltooid
        • Fondazione Istituto Neurologico Casimiro Mondino
      • Roma, Italië, 00168
        • Voltooid
        • Fondazione Policlinico Universitario A Gemelli IRCCS
      • Rozzano, Italië, 20086
        • Voltooid
        • IRCCS Istituto Clinico Humanitas
      • Asahikawa, Japan, 070-0901
        • Actief, niet wervend
        • National Hospital Organization Asahikawa Medical Center
      • Bunkyō City, Japan, 113 8519
        • Actief, niet wervend
        • Institute of Science Tokyo Hospital
      • Chiba, Japan, 260-8677
        • Voltooid
        • Chiba University Hospital
      • Hamamatsu, Japan, 430-8558
        • Actief, niet wervend
        • Seirei Hamamatsu General Hospital
      • Isehara, Japan, 259-1193
        • Actief, niet wervend
        • Tokai University Hospital
      • Kobe, Japan, 650 0047
        • Voltooid
        • Kobe City Medical Center General Hospital
      • Kodaira-shi, Japan, 187-8551
        • Actief, niet wervend
        • National Center of Neurology and Psychiatry
      • Koshigaya, Japan, 343-8555
        • Actief, niet wervend
        • Saitama Medical Center
      • Kumamoto, Japan, 860-8556
        • Voltooid
        • Kumamoto University Hospital
      • Nagoya, Japan, 466-8560
        • Actief, niet wervend
        • Nagoya University Hospital
      • Nagoya, Japan, 455-8530
        • Actief, niet wervend
        • Chubu Rosai Hospital
      • Osaka Sayama Shi, Japan, 589 8511
        • Voltooid
        • Kindai University Hospital
      • Sendai, Japan, 983-8520
        • Actief, niet wervend
        • National Hospital Organization Sendai Medical Center
      • Shimotsuga Gun, Japan, 321 0293
        • Voltooid
        • Dokkyo Medical University Hospital
      • Shinjuku-ku, Japan, 162-8666
        • Voltooid
        • Tokyo Women's Medical University Hospital
      • Tenri, Japan, 632-0015
        • Voltooid
        • Tenri Hospital
      • Toon-shi, Japan, 791-0295
        • Voltooid
        • Ehime University Hospital
      • Toyama, Japan, 930-0194
        • Voltooid
        • Toyama University Hospital
      • Ube, Japan, 755-8505
        • Voltooid
        • Yamaguchi University Hospital
      • Monterrey, Mexico, 64710
        • Voltooid
        • i Can Oncology Center
      • Tlalnepantla, Mexico, 54055
        • Werving
        • Clinical Research Institute S.C.
      • Chorzów, Polen, 41 500
        • Voltooid
        • Centrum Medyczne
      • Krakow, Polen, 30 539
        • Voltooid
        • Specjalistyczne Gabinety Lekarskie
      • Lublin, Polen, 20 093
        • Voltooid
        • Prywatny Gabinet Lekarski
      • Poznan, Polen, 61 731
        • Actief, niet wervend
        • Clinical Research Center sp z o o MEDIC R s k
      • Almada, Portugal, 2805-267
        • Actief, niet wervend
        • Hospital Garcia de Orta
      • Braga, Portugal, 4710-243
        • Voltooid
        • Hospital de Braga
      • Porto, Portugal, 4200 319
        • Actief, niet wervend
        • Centro Hospitalar de Sao Joao Epe
      • Alicante, Spanje, 03010
        • Actief, niet wervend
        • Hosp. Gral. Univ. de Alicante
      • Barcelona, Spanje, 8035
        • Voltooid
        • Hosp Univ Vall D Hebron
      • Bilbao, Spanje, 48013
        • Actief, niet wervend
        • Hosp. Univ. de Basurto
      • Donostia / San Sebastian, Spanje, 20014
        • Voltooid
        • Hosp. Univ. Donostia
      • Madrid, Spanje, 28040
        • Voltooid
        • Hosp. Clinico San Carlos
      • Seville, Spanje, 41009
        • Actief, niet wervend
        • Hosp. Virgen Macarena
      • Kaohsiung City, Taiwan, 88301
        • Voltooid
        • Kaohsiung Chang Gung Memorial Hospital
      • Taipei, Taiwan, 100
        • Actief, niet wervend
        • National Taiwan University Hospital
      • Taipei, Taiwan, 111
        • Actief, niet wervend
        • Shin Kong Wu Ho Su Memorial Hospital
      • Hradec Králové, Tsjechië, 500 05
        • Actief, niet wervend
        • Fakultni nemocnice Hradec Kralove
      • Ostrava, Tsjechië, 708 52
        • Voltooid
        • Fakultni Nemocnice Ostrava
      • Pardubice, Tsjechië, 53203
        • Voltooid
        • Pardubicka krajska nemocnice a s
      • Birmingham, Verenigd Koninkrijk, B15 2TH
        • Voltooid
        • University Hospitals Birmingham NHS Foundation Trust
      • Devon, Verenigd Koninkrijk, EX2 5DW
        • Voltooid
        • Royal Devon & Exeter Hospital
      • Glasgow, Verenigd Koninkrijk, G514TF
        • Actief, niet wervend
        • NHS Greater Glasgow and Clyde
      • London, Verenigd Koninkrijk, NW3 2QG
        • Voltooid
        • Royal Free Hospital
      • Sheffield, Verenigd Koninkrijk, S10 2 JF
        • Actief, niet wervend
        • Sheffield Teaching Hospitals NHS Foundation Trust
    • Colorado
      • Centennial, Colorado, Verenigde Staten, 80112
        • Actief, niet wervend
        • IMMUNOe Health and Research Centers
    • Florida
      • Coral Springs, Florida, Verenigde Staten, 33067
        • Voltooid
        • Healthcare Innovations Institute Inc
      • Maitland, Florida, Verenigde Staten, 32751
        • Voltooid
        • Neurology Associates PA
      • Miami, Florida, Verenigde Staten, 33136
        • Actief, niet wervend
        • ALS Center at the University of Miami
    • Georgia
      • Augusta, Georgia, Verenigde Staten, 30912
        • Voltooid
        • Augusta University
    • Kansas
      • Kansas City, Kansas, Verenigde Staten, 66160
        • Voltooid
        • University of Kansas Medical Center
    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21287
        • Voltooid
        • Johns Hopkins Hospital
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02111
        • Voltooid
        • Boston Clinical Trials
    • Michigan
      • Royal Oak, Michigan, Verenigde Staten, 48073
        • Voltooid
        • Beaumont Hospital Royal Oak
    • Missouri
      • Kansas City, Missouri, Verenigde Staten, 64128
        • Voltooid
        • Kansas City Veterans Affairs Medical Center
    • New York
      • New York, New York, Verenigde Staten, 10032
        • Voltooid
        • The Neurological Institute of New York
      • Patchogue, New York, Verenigde Staten, 11772
        • Voltooid
        • South Shore Neurologic Associates - Patchogue
    • North Carolina
      • Charlotte, North Carolina, Verenigde Staten, 28204
        • Voltooid
        • The Neurological Institute, PA
    • Ohio
      • Cleveland, Ohio, Verenigde Staten, 44195
        • Actief, niet wervend
        • Cleveland Clinic Main Campus
    • Texas
      • Austin, Texas, Verenigde Staten, 78756
        • Voltooid
        • Austin Neuromuscular Center
    • Wisconsin
      • Milwaukee, Wisconsin, Verenigde Staten, 53215
        • Actief, niet wervend
        • Advocate Health - Aurora St. Luke's Medical Center
      • Seoul, Zuid -Korea, 05030
        • Voltooid
        • Konkuk University Medical Center
      • Seoul, Zuid -Korea, 02447
        • Voltooid
        • Kyunghee University Medical Center
      • Seoul, Zuid -Korea, 135-710
        • Voltooid
        • Samsung Medical Center

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Adults greater than or equal to (>=) 18 years of age at the time of consent and as applicable, must also meet the legal age of consent in the jurisdiction in which the study is taking place
  • Diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) according to criteria of the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021, progressing or relapsing forms. CIDP diagnosis to be adjudicated by independent committee during screening period
  • Inflammatory Neuropathy Cause and Treatment (INCAT) disability score between 2 and 9 at the Run-In Baseline visit for participants entering Run-In, or Stage A Baseline visit for participants directly entering Stage A. Participants with an INCAT score of 2 at trial entry must have this score exclusively from the leg disability score
  • Fulfilling any of the following treatment conditions: a) Currently treated with oral corticosteroids (CS) less than or equal to (<=) 20 milligrams (mg)/day; or b) Currently treated with pulsed CS, and/or intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) and the participant is willing to discontinue no later than the run-in baseline visit; or c) Currently treated with oral CS greater than (>) 20 mg/day and the participant is willing to taper to <=20 mg/day during the run-in period; or d) Without previous treatment (treatment naive); or treatment with CS and/or IVIg or SCIg discontinued at least 3 months prior to screening (untreated)
  • Active disease as determined by CIDP Disease Activity Status (CDAS) score >= 3
  • Other protocol-defined inclusion criteria will apply

Exclusion Criteria:

  • Has a history of severe and/or uncontrolled hepatic (example, viral/alcoholic/autoimmune hepatitis/cirrhosis and/or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological or musculoskeletal disorder, hypertension and/or any other medical or uncontrolled autoimmune disorder(s) (example, diabetes mellitus) or clinically significant abnormalities in screening laboratory that, might interfere with the participants full participation in the study, or might jeopardize the safety of the participant or the validity of the study results
  • Pure sensory CIDP or chronic immune sensory polyradiculopathy (CISP) (EAN/PNS definition)
  • Any other disease that could better explain the participant's signs and symptoms, such as significant persisting neurological deficits from stroke or central nervous system (CNS) trauma or peripheral neuropathy from another cause such as connective tissue disease or systemic lupus erythematosus
  • Polyneuropathy of other causes, including the following: Multifocal motor neuropathy (MMN); Monoclonal gammopathy of uncertain significance with antimyelin associated glycoprotein (anti-MAG) immunoglobulin M (IgM) antibodies; Hereditary motor neuropathy; Hereditary neuropathy with liability to pressure palsies (HNPP); Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or toxin-induced polyneuropathy Note: A concomitant polyneuropathy of other causes (example, a mild, stable diabetic polyneuropathy) is not necessarily exclusionary if chronic inflammatory demyelinating polyneuropathy (CIDP) is confirmed as the main diagnosis, as determined by the investigator and confirmed by the adjudication committee
  • Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients
  • Other protocol-defined exclusion criteria will apply

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Nipocalimab

Participants in Stage A (Open-label) will receive a loading dose of nipocalimab (Dose 1) intravenous (IV) infusion on Day 1, followed by nipocalimab (Dose 2) IV infusion once every 2 weeks (q2w) from Week 2 to Week 12. Participants who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive nipocalimab (Dose 2) IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first.

Nipocalimab will be administered intravenously.

Andere namen:
  • JNJ-80202135
  • M281
Placebo-vergelijker: Placebo

Participants receiving nipocalimab in Stage A and who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive placebo IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first.

Placebo will be administered intravenously.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Stage B: Time to First Occurrence of a Relapse Event
Tijdsspanne: Up to 52 weeks

Stage B time to first occurrence of a relapse event will be reported.

Up to 52 weeks

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI)
Tijdsspanne: 12 weeks

Time to initial confirmed ECI will be reported.

12 weeks
Stage A: Percentage of Responders as Determined by ECI
Tijdsspanne: 12 weeks

Stage A percentage of responders as determined by ECI will be reported.

12 weeks
Stage A: Change from Baseline Over Time in Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale Score
Tijdsspanne: Baseline to 12 weeks

Change from Stage A baseline over time in adjusted INCAT disability scale score will be reported. The INCAT disability scale is a clinician-rated assessment that measures activity limitation and degree of functional disability. The INCAT scale is an ordinal scale scored from 0 to 10, with higher scores indicating more disability.

Baseline to 12 weeks
Stage A: Change from Stage A Baseline Over Time in Medical Research Council (MRC) Muscle Grading Scale Sum Score
Tijdsspanne: Baseline to 12 weeks

Change from Stage A baseline over time in MRC muscle grading scale sum score will be reported. The MRC muscle grading scale is a clinician-rated outcome that provides a strength rating (on a scale from 0 [no visible contraction] to 5 [normal]) in 6 muscles collected bilaterally: deltoid, biceps, wrist extensors, iliopsoas, quadriceps, tibialis anterior. Lower scores indicate greater impairment.

Baseline to 12 weeks
Stage A: Change from Baseline Over Time in Inflammatory Rasch-Built Overall Disability Scale (I-RODS) Centile Score
Tijdsspanne: Baseline to 12 weeks

Change from Stage A baseline over time in I-RODS centile score will be reported. The I-RODS comprises of 24 items representing common daily activities that address upper and lower limb disability and range in difficulty from very easy to very difficult. Lower scores indicate greater activity and social participation limitations.

Baseline to 12 weeks
Stage A: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Tijdsspanne: Baseline to 12 weeks

Change from Stage A baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Baseline to 12 weeks
Stage A: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Tijdsspanne: Baseline to 12 weeks

Change from Stage A baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Baseline to 12 weeks
Stage B: Time to First Adjusted INCAT Disability Scale Score Deterioration Relative to Baseline
Tijdsspanne: Up to 52 weeks

Time to first adjusted INCAT disability scale score deterioration relative to Stage B baseline will be reported.

Up to 52 weeks
Stage B: Time to First Switch to Intravenous Immunoglobulin (IVIg) or Other Standard of Care (SoC) as a Result of Investigator-assessed Lack of Efficacy as Confirmed by an Independent RAC Relative to Baseline
Tijdsspanne: Up to 52 weeks

Time to first switch to IVIg or other SoC as a result of investigator-assessed lack of efficacy as confirmed by an independent Relapse Adjudication Committee (RAC) relative to Stage B baseline will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in Adjusted INCAT Disability Score
Tijdsspanne: Up to 52 weeks

Change from Stage B baseline over time in adjusted INCAT disability score will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in MRC Muscle Grading Scale Sum Score
Tijdsspanne: Up to 52 weeks

Change from Stage B baseline over time in MRC Muscle Grading Scale Sum score will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in I-RODS Centile Score
Tijdsspanne: Up to 52 weeks

Change from Stage B baseline over time in I-RODS centile score will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Tijdsspanne: Up to 52 weeks

Change from Stage B baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Up to 52 weeks
Stage B: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Tijdsspanne: Up to 52 weeks

Change from Stage B baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Up to 52 weeks
Stage B: Number of Participants with Binary Response Endpoint Satisfying all 4 Conditions: a) An Improved Adjusted INCAT Disability Score Compared to Baseline; b) Not Relapsing; c) Not Switching to SoC; d) Not Discontinuing Treatment
Tijdsspanne: Up to 52 weeks

Number of participants with Binary response endpoint satisfying all 4 conditions: a) an improved adjusted INCAT Disability Score compared to Stage B baseline; b) not relapsing; c) not switching to SoC; d) not discontinuing treatment, will be reported.

Up to 52 weeks
Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks

An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment

Stage A: 12 weeks; Stage B: Up to 52 weeks
Percentage of Participants with Serious Adverse Events (SAEs)
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks

SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Change in Electrocardiogram (ECG) Values Over Time
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with change in ECG values over time will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Change in Vital Signs Values Over Time
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with change in vital signs values over time will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Change in Clinical Laboratory Values Over Time
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with change in clinical laboratory values over time will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Clinically Significant ECG Abnormalities
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with clinically significant ECG abnormalities will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Clinically Significant Vital Signs Abnormalities
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with clinically significant vital signs abnormalities will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Clinically Significant Clinical Laboratory Abnormalities
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with clinically significant clinical laboratory abnormalities will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Percentage of Participants with Suicidal Ideation or Suicidal Behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks

Percentage of participants with suicidal ideation or suicidal behavior based on the C-SSRS will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Serum Nipocalimab Concentrations Over Time in Participants Receiving Active Study Intervention
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks

Serum nipocalimab concentrations over time in participants receiving active study intervention will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Anti-drug Antibodies (ADA) to Nipocalimab
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with ADA to Nipocalimab will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Titers of ADA to Nipocalimab
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks

Titers of ADA to nipocalimab will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Neutralizing Antibodies (NAb) to Nipocalimab
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with NAb to Nipocalimab will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Change from Baseline in Total Serum Immunoglobulin (IgG) Concentrations Levels Over Time
Tijdsspanne: Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks

Change from baseline in total serum IgG concentrations levels over time will be reported.

Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

23 september 2022

Primaire voltooiing (Geschat)

15 december 2026

Studie voltooiing (Geschat)

11 juli 2028

Studieregistratiedata

Eerst ingediend

7 april 2022

Eerst ingediend dat voldeed aan de QC-criteria

7 april 2022

Eerst geplaatst (Werkelijk)

14 april 2022

Updates van studierecords

Laatste update geplaatst (Werkelijk)

3 november 2026

Laatste update ingediend die voldeed aan QC-criteria

2 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • CR109195
  • 80202135CDP3001 (Andere identificatie: Janssen Research & Development, LLC)
  • 2021-003234-37 (EudraCT-nummer)
  • 2023-508425-28-00 (Register-ID: EUCT number)
  • 2023 (Subsidie/contract van de Amerikaanse NIH)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren